nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—EPHB1—tongue—salivary gland cancer	0.0137	0.0417	CbGeAlD
Dasatinib—WEE2—lymphoid tissue—salivary gland cancer	0.00693	0.0211	CbGeAlD
Dasatinib—PKMYT1—neck—salivary gland cancer	0.00677	0.0206	CbGeAlD
Dasatinib—EPHA4—tongue—salivary gland cancer	0.00618	0.0189	CbGeAlD
Dasatinib—TEC—lymphoid tissue—salivary gland cancer	0.00525	0.016	CbGeAlD
Dasatinib—SIK2—connective tissue—salivary gland cancer	0.00498	0.0152	CbGeAlD
Dasatinib—PTK6—saliva-secreting gland—salivary gland cancer	0.00483	0.0147	CbGeAlD
Dasatinib—SRMS—connective tissue—salivary gland cancer	0.00453	0.0138	CbGeAlD
Dasatinib—BMX—epithelium—salivary gland cancer	0.00449	0.0137	CbGeAlD
Dasatinib—STAT5B—connective tissue—salivary gland cancer	0.00419	0.0128	CbGeAlD
Dasatinib—STAT5B—epithelium—salivary gland cancer	0.00398	0.0121	CbGeAlD
Dasatinib—FRK—lymphoid tissue—salivary gland cancer	0.00355	0.0108	CbGeAlD
Dasatinib—TESK1—parotid gland—salivary gland cancer	0.00352	0.0107	CbGeAlD
Dasatinib—BLK—lymphoid tissue—salivary gland cancer	0.00342	0.0104	CbGeAlD
Dasatinib—LYN—connective tissue—salivary gland cancer	0.00341	0.0104	CbGeAlD
Dasatinib—EPHB2—lymphoid tissue—salivary gland cancer	0.00338	0.0103	CbGeAlD
Dasatinib—TESK1—saliva-secreting gland—salivary gland cancer	0.00337	0.0103	CbGeAlD
Dasatinib—BTK—connective tissue—salivary gland cancer	0.00334	0.0102	CbGeAlD
Dasatinib—EPHB3—saliva-secreting gland—salivary gland cancer	0.00332	0.0101	CbGeAlD
Dasatinib—MAPK14—neck—salivary gland cancer	0.00328	0.01	CbGeAlD
Dasatinib—TXK—lymphoid tissue—salivary gland cancer	0.00328	0.00999	CbGeAlD
Dasatinib—CSK—parotid gland—salivary gland cancer	0.00323	0.00984	CbGeAlD
Dasatinib—BMPR1B—epithelium—salivary gland cancer	0.00319	0.00973	CbGeAlD
Dasatinib—TESK1—connective tissue—salivary gland cancer	0.0031	0.00945	CbGeAlD
Dasatinib—CSK—saliva-secreting gland—salivary gland cancer	0.00309	0.00942	CbGeAlD
Dasatinib—STAT5B—lymphoid tissue—salivary gland cancer	0.00307	0.00935	CbGeAlD
Dasatinib—RIPK2—parotid gland—salivary gland cancer	0.00299	0.00913	CbGeAlD
Dasatinib—TEC—lymph node—salivary gland cancer	0.00296	0.00903	CbGeAlD
Dasatinib—SIK1—parotid gland—salivary gland cancer	0.00292	0.00892	CbGeAlD
Dasatinib—RIPK2—saliva-secreting gland—salivary gland cancer	0.00287	0.00875	CbGeAlD
Dasatinib—CSK—connective tissue—salivary gland cancer	0.00284	0.00866	CbGeAlD
Dasatinib—SIK1—saliva-secreting gland—salivary gland cancer	0.0028	0.00854	CbGeAlD
Dasatinib—ERBB3—saliva-secreting gland—salivary gland cancer	0.00275	0.00837	CbGeAlD
Dasatinib—RIPK2—connective tissue—salivary gland cancer	0.00264	0.00804	CbGeAlD
Dasatinib—SIK1—connective tissue—salivary gland cancer	0.00257	0.00785	CbGeAlD
Dasatinib—FMO3—parotid gland—salivary gland cancer	0.00257	0.00783	CbGeAlD
Dasatinib—ZAK—lymphoid tissue—salivary gland cancer	0.00256	0.00782	CbGeAlD
Dasatinib—EPHB4—parotid gland—salivary gland cancer	0.00253	0.00772	CbGeAlD
Dasatinib—ERBB3—connective tissue—salivary gland cancer	0.00252	0.00769	CbGeAlD
Dasatinib—RIPK2—epithelium—salivary gland cancer	0.0025	0.00763	CbGeAlD
Dasatinib—MAP3K2—connective tissue—salivary gland cancer	0.0025	0.00762	CbGeAlD
Dasatinib—LYN—lymphoid tissue—salivary gland cancer	0.0025	0.00761	CbGeAlD
Dasatinib—EPHA2—parotid gland—salivary gland cancer	0.00248	0.00757	CbGeAlD
Dasatinib—BTK—lymphoid tissue—salivary gland cancer	0.00245	0.00746	CbGeAlD
Dasatinib—EPHB4—saliva-secreting gland—salivary gland cancer	0.00242	0.00739	CbGeAlD
Dasatinib—MAP4K5—parotid gland—salivary gland cancer	0.00242	0.00739	CbGeAlD
Dasatinib—MAP3K3—parotid gland—salivary gland cancer	0.00242	0.00739	CbGeAlD
Dasatinib—ERBB3—epithelium—salivary gland cancer	0.00239	0.0073	CbGeAlD
Dasatinib—EPHA2—saliva-secreting gland—salivary gland cancer	0.00238	0.00725	CbGeAlD
Dasatinib—MAPK14—connective tissue—salivary gland cancer	0.00235	0.00716	CbGeAlD
Dasatinib—EPHB1—lymph node—salivary gland cancer	0.00232	0.00709	CbGeAlD
Dasatinib—MAP3K3—saliva-secreting gland—salivary gland cancer	0.00232	0.00707	CbGeAlD
Dasatinib—MAP4K5—saliva-secreting gland—salivary gland cancer	0.00232	0.00707	CbGeAlD
Dasatinib—EPHB6—parotid gland—salivary gland cancer	0.00231	0.00706	CbGeAlD
Dasatinib—YES1—parotid gland—salivary gland cancer	0.00224	0.00682	CbGeAlD
Dasatinib—MAPK14—epithelium—salivary gland cancer	0.00223	0.0068	CbGeAlD
Dasatinib—EPHB4—connective tissue—salivary gland cancer	0.00223	0.00679	CbGeAlD
Dasatinib—EPHB6—saliva-secreting gland—salivary gland cancer	0.00222	0.00676	CbGeAlD
Dasatinib—JAK2—connective tissue—salivary gland cancer	0.00221	0.00674	CbGeAlD
Dasatinib—FYN—connective tissue—salivary gland cancer	0.00218	0.00665	CbGeAlD
Dasatinib—LIMK2—lymphoid tissue—salivary gland cancer	0.00216	0.00658	CbGeAlD
Dasatinib—KIT—neck—salivary gland cancer	0.00215	0.00657	CbGeAlD
Dasatinib—YES1—saliva-secreting gland—salivary gland cancer	0.00214	0.00653	CbGeAlD
Dasatinib—EPHB4—epithelium—salivary gland cancer	0.00211	0.00645	CbGeAlD
Dasatinib—PDGFRB—neck—salivary gland cancer	0.0021	0.00641	CbGeAlD
Dasatinib—JAK2—epithelium—salivary gland cancer	0.0021	0.0064	CbGeAlD
Dasatinib—CSK—lymphoid tissue—salivary gland cancer	0.00208	0.00633	CbGeAlD
Dasatinib—EPHA2—epithelium—salivary gland cancer	0.00207	0.00632	CbGeAlD
Dasatinib—HCK—lymphoid tissue—salivary gland cancer	0.00205	0.00625	CbGeAlD
Dasatinib—MAP2K5—parotid gland—salivary gland cancer	0.00198	0.00604	CbGeAlD
Dasatinib—YES1—connective tissue—salivary gland cancer	0.00197	0.006	CbGeAlD
Dasatinib—BMX—lymph node—salivary gland cancer	0.00195	0.00596	CbGeAlD
Dasatinib—PDGFRA—connective tissue—salivary gland cancer	0.00193	0.00589	CbGeAlD
Dasatinib—BLK—lymph node—salivary gland cancer	0.00193	0.00589	CbGeAlD
Dasatinib—MAP2K5—saliva-secreting gland—salivary gland cancer	0.0019	0.00578	CbGeAlD
Dasatinib—SRC—connective tissue—salivary gland cancer	0.00189	0.00577	CbGeAlD
Dasatinib—SIK1—lymphoid tissue—salivary gland cancer	0.00188	0.00574	CbGeAlD
Dasatinib—TXK—lymph node—salivary gland cancer	0.00185	0.00564	CbGeAlD
Dasatinib—ERBB3—lymphoid tissue—salivary gland cancer	0.00184	0.00563	CbGeAlD
Dasatinib—MAP3K2—lymphoid tissue—salivary gland cancer	0.00183	0.00557	CbGeAlD
Dasatinib—SRC—epithelium—salivary gland cancer	0.0018	0.00548	CbGeAlD
Dasatinib—KIT—parotid gland—salivary gland cancer	0.00175	0.00535	CbGeAlD
Dasatinib—STAT5B—lymph node—salivary gland cancer	0.00173	0.00528	CbGeAlD
Dasatinib—MAPK14—lymphoid tissue—salivary gland cancer	0.00172	0.00524	CbGeAlD
Dasatinib—PDGFRB—parotid gland—salivary gland cancer	0.00171	0.00522	CbGeAlD
Dasatinib—FGR—lymphoid tissue—salivary gland cancer	0.00171	0.00522	CbGeAlD
Dasatinib—CSF1R—connective tissue—salivary gland cancer	0.0017	0.00518	CbGeAlD
Dasatinib—KIT—saliva-secreting gland—salivary gland cancer	0.00168	0.00512	CbGeAlD
Dasatinib—PDGFRB—saliva-secreting gland—salivary gland cancer	0.00164	0.005	CbGeAlD
Dasatinib—JAK2—lymphoid tissue—salivary gland cancer	0.00162	0.00493	CbGeAlD
Dasatinib—EPHA3—lymph node—salivary gland cancer	0.0016	0.00488	CbGeAlD
Dasatinib—EPHA2—lymphoid tissue—salivary gland cancer	0.0016	0.00487	CbGeAlD
Dasatinib—FYN—lymphoid tissue—salivary gland cancer	0.00159	0.00486	CbGeAlD
Dasatinib—MAP4K5—lymphoid tissue—salivary gland cancer	0.00156	0.00475	CbGeAlD
Dasatinib—SIK3—lymph node—salivary gland cancer	0.00156	0.00475	CbGeAlD
Dasatinib—KIT—connective tissue—salivary gland cancer	0.00154	0.00471	CbGeAlD
Dasatinib—ABL1—parotid gland—salivary gland cancer	0.00153	0.00466	CbGeAlD
Dasatinib—PDGFRB—connective tissue—salivary gland cancer	0.00151	0.0046	CbGeAlD
Dasatinib—KIT—epithelium—salivary gland cancer	0.00147	0.00447	CbGeAlD
Dasatinib—ABL1—saliva-secreting gland—salivary gland cancer	0.00146	0.00446	CbGeAlD
Dasatinib—ZAK—lymph node—salivary gland cancer	0.00145	0.00441	CbGeAlD
Dasatinib—YES1—lymphoid tissue—salivary gland cancer	0.00144	0.00439	CbGeAlD
Dasatinib—PDGFRB—epithelium—salivary gland cancer	0.00143	0.00436	CbGeAlD
Dasatinib—PDGFRA—lymphoid tissue—salivary gland cancer	0.00141	0.00431	CbGeAlD
Dasatinib—BMPR1B—lymph node—salivary gland cancer	0.00139	0.00423	CbGeAlD
Dasatinib—SRC—lymphoid tissue—salivary gland cancer	0.00138	0.00422	CbGeAlD
Dasatinib—BTK—lymph node—salivary gland cancer	0.00138	0.00421	CbGeAlD
Dasatinib—TNK2—lymph node—salivary gland cancer	0.00136	0.00415	CbGeAlD
Dasatinib—ABL1—connective tissue—salivary gland cancer	0.00134	0.0041	CbGeAlD
Dasatinib—TESK1—lymph node—salivary gland cancer	0.00128	0.0039	CbGeAlD
Dasatinib—STK36—lymph node—salivary gland cancer	0.00126	0.00384	CbGeAlD
Dasatinib—EPHB3—lymph node—salivary gland cancer	0.00126	0.00384	CbGeAlD
Dasatinib—CSF1R—lymphoid tissue—salivary gland cancer	0.00124	0.00379	CbGeAlD
Dasatinib—LIMK2—lymph node—salivary gland cancer	0.00122	0.00371	CbGeAlD
Dasatinib—STK35—lymph node—salivary gland cancer	0.00118	0.0036	CbGeAlD
Dasatinib—CSK—lymph node—salivary gland cancer	0.00117	0.00357	CbGeAlD
Dasatinib—HCK—lymph node—salivary gland cancer	0.00116	0.00353	CbGeAlD
Dasatinib—ABL2—lymph node—salivary gland cancer	0.00115	0.0035	CbGeAlD
Dasatinib—CYP1B1—connective tissue—salivary gland cancer	0.00114	0.00347	CbGeAlD
Dasatinib—KIT—lymphoid tissue—salivary gland cancer	0.00113	0.00344	CbGeAlD
Dasatinib—PDGFRB—lymphoid tissue—salivary gland cancer	0.0011	0.00336	CbGeAlD
Dasatinib—RIPK2—lymph node—salivary gland cancer	0.00109	0.00332	CbGeAlD
Dasatinib—SIK1—lymph node—salivary gland cancer	0.00106	0.00324	CbGeAlD
Dasatinib—EPHA4—lymph node—salivary gland cancer	0.00105	0.00321	CbGeAlD
Dasatinib—ERBB3—lymph node—salivary gland cancer	0.00104	0.00317	CbGeAlD
Dasatinib—MAP3K2—lymph node—salivary gland cancer	0.00103	0.00314	CbGeAlD
Dasatinib—ABL1—lymphoid tissue—salivary gland cancer	0.000982	0.003	CbGeAlD
Dasatinib—MAPK14—lymph node—salivary gland cancer	0.000969	0.00296	CbGeAlD
Dasatinib—FGR—lymph node—salivary gland cancer	0.000965	0.00294	CbGeAlD
Dasatinib—LCK—lymph node—salivary gland cancer	0.000965	0.00294	CbGeAlD
Dasatinib—ABCG2—parotid gland—salivary gland cancer	0.000963	0.00294	CbGeAlD
Dasatinib—FMO3—lymph node—salivary gland cancer	0.000932	0.00284	CbGeAlD
Dasatinib—ABCG2—saliva-secreting gland—salivary gland cancer	0.000922	0.00281	CbGeAlD
Dasatinib—EPHB4—lymph node—salivary gland cancer	0.000919	0.0028	CbGeAlD
Dasatinib—CYP1A1—parotid gland—salivary gland cancer	0.000914	0.00279	CbGeAlD
Dasatinib—JAK2—lymph node—salivary gland cancer	0.000912	0.00278	CbGeAlD
Dasatinib—EPHA2—lymph node—salivary gland cancer	0.000901	0.00275	CbGeAlD
Dasatinib—FYN—lymph node—salivary gland cancer	0.0009	0.00274	CbGeAlD
Dasatinib—MAP4K5—lymph node—salivary gland cancer	0.000879	0.00268	CbGeAlD
Dasatinib—MAP3K3—lymph node—salivary gland cancer	0.000879	0.00268	CbGeAlD
Dasatinib—EPHB6—lymph node—salivary gland cancer	0.00084	0.00256	CbGeAlD
Dasatinib—CYP1B1—lymphoid tissue—salivary gland cancer	0.000832	0.00254	CbGeAlD
Dasatinib—YES1—lymph node—salivary gland cancer	0.000812	0.00248	CbGeAlD
Dasatinib—PDGFRA—lymph node—salivary gland cancer	0.000796	0.00243	CbGeAlD
Dasatinib—SRC—lymph node—salivary gland cancer	0.000781	0.00238	CbGeAlD
Dasatinib—CYP1A1—epithelium—salivary gland cancer	0.000764	0.00233	CbGeAlD
Dasatinib—MAP2K5—lymph node—salivary gland cancer	0.000718	0.00219	CbGeAlD
Dasatinib—CSF1R—lymph node—salivary gland cancer	0.000701	0.00214	CbGeAlD
Dasatinib—KIT—lymph node—salivary gland cancer	0.000637	0.00194	CbGeAlD
Dasatinib—PDGFRB—lymph node—salivary gland cancer	0.000622	0.0019	CbGeAlD
Dasatinib—ABL1—lymph node—salivary gland cancer	0.000554	0.00169	CbGeAlD
Dasatinib—CYP1B1—lymph node—salivary gland cancer	0.000469	0.00143	CbGeAlD
Dasatinib—ABCB1—epithelium—salivary gland cancer	0.000397	0.00121	CbGeAlD
Dasatinib—ABCG2—lymph node—salivary gland cancer	0.00035	0.00107	CbGeAlD
Dasatinib—CYP1A1—lymph node—salivary gland cancer	0.000332	0.00101	CbGeAlD
Dasatinib—ABCB1—lymphoid tissue—salivary gland cancer	0.000305	0.000932	CbGeAlD
Dasatinib—ABCB1—lymph node—salivary gland cancer	0.000172	0.000526	CbGeAlD
Dasatinib—ABL1—Innate Immune System—HRAS—salivary gland cancer	1.06e-05	1.57e-05	CbGpPWpGaD
Dasatinib—HCK—Disease—HRAS—salivary gland cancer	1.05e-05	1.56e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—PTEN—salivary gland cancer	1.05e-05	1.56e-05	CbGpPWpGaD
Dasatinib—FYN—Innate Immune System—HRAS—salivary gland cancer	1.05e-05	1.56e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—PIK3CA—salivary gland cancer	1.05e-05	1.56e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Adaptive Immune System—HRAS—salivary gland cancer	1.04e-05	1.55e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—PIK3CA—salivary gland cancer	1.04e-05	1.54e-05	CbGpPWpGaD
Dasatinib—BLK—Immune System—HRAS—salivary gland cancer	1.03e-05	1.53e-05	CbGpPWpGaD
Dasatinib—FGR—Immune System—HRAS—salivary gland cancer	1.03e-05	1.53e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—CREBBP—salivary gland cancer	1.03e-05	1.53e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—FOXO3—salivary gland cancer	1.03e-05	1.53e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—EP300—salivary gland cancer	1.02e-05	1.52e-05	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—PIK3CA—salivary gland cancer	1.02e-05	1.52e-05	CbGpPWpGaD
Dasatinib—LYN—Adaptive Immune System—HRAS—salivary gland cancer	1.02e-05	1.52e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism of lipids and lipoproteins—PIK3CA—salivary gland cancer	1.01e-05	1.51e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—EP300—salivary gland cancer	1.01e-05	1.51e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—TP53—salivary gland cancer	1.01e-05	1.5e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PHGDH—salivary gland cancer	1.01e-05	1.5e-05	CbGpPWpGaD
Dasatinib—MAPK14—Innate Immune System—HRAS—salivary gland cancer	1.01e-05	1.5e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—CCND1—salivary gland cancer	1.01e-05	1.5e-05	CbGpPWpGaD
Dasatinib—FMO3—Metabolism—PIK3CA—salivary gland cancer	1.01e-05	1.5e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—CREBBP—salivary gland cancer	1e-05	1.49e-05	CbGpPWpGaD
Dasatinib—FYN—Adaptive Immune System—HRAS—salivary gland cancer	1e-05	1.49e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—PIK3CA—salivary gland cancer	1e-05	1.49e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—TP53—salivary gland cancer	1e-05	1.49e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—EP300—salivary gland cancer	9.99e-06	1.49e-05	CbGpPWpGaD
Dasatinib—JAK2—Innate Immune System—HRAS—salivary gland cancer	9.94e-06	1.48e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—PTEN—salivary gland cancer	9.92e-06	1.48e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—NOTCH1—salivary gland cancer	9.81e-06	1.46e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—CREBBP—salivary gland cancer	9.73e-06	1.45e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ST3GAL4—salivary gland cancer	9.72e-06	1.45e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—PTEN—salivary gland cancer	9.71e-06	1.45e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—TP53—salivary gland cancer	9.71e-06	1.44e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—CCND1—salivary gland cancer	9.7e-06	1.44e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—PTEN—salivary gland cancer	9.68e-06	1.44e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—HRAS—salivary gland cancer	9.67e-06	1.44e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—NOTCH1—salivary gland cancer	9.67e-06	1.44e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—CREBBP—salivary gland cancer	9.63e-06	1.43e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—HRAS—salivary gland cancer	9.59e-06	1.43e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—CDH1—salivary gland cancer	9.56e-06	1.42e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—PTEN—salivary gland cancer	9.48e-06	1.41e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MAP2K2—salivary gland cancer	9.47e-06	1.41e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—NOTCH1—salivary gland cancer	9.46e-06	1.41e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—EP300—salivary gland cancer	9.46e-06	1.41e-05	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—HRAS—salivary gland cancer	9.45e-06	1.41e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—PTEN—salivary gland cancer	9.43e-06	1.4e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—PIK3CA—salivary gland cancer	9.43e-06	1.4e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—PIK3CA—salivary gland cancer	9.41e-06	1.4e-05	CbGpPWpGaD
Dasatinib—ABCB1—Transmembrane transport of small molecules—CREBBP—salivary gland cancer	9.41e-06	1.4e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—PTEN—salivary gland cancer	9.36e-06	1.39e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—PTEN—salivary gland cancer	9.33e-06	1.39e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—NOTCH1—salivary gland cancer	9.32e-06	1.39e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—HRAS—salivary gland cancer	9.28e-06	1.38e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—EP300—salivary gland cancer	9.26e-06	1.38e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—PIK3CA—salivary gland cancer	9.25e-06	1.38e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—EP300—salivary gland cancer	9.23e-06	1.37e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—NUP62—salivary gland cancer	9.07e-06	1.35e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—EP300—salivary gland cancer	9.04e-06	1.34e-05	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—PIK3CA—salivary gland cancer	9.04e-06	1.34e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—VCAN—salivary gland cancer	9e-06	1.34e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—EP300—salivary gland cancer	9e-06	1.34e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—PTEN—salivary gland cancer	8.98e-06	1.34e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—NOTCH1—salivary gland cancer	8.97e-06	1.33e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—PIK3CA—salivary gland cancer	8.97e-06	1.33e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—CREBBP—salivary gland cancer	8.96e-06	1.33e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—TP53—salivary gland cancer	8.95e-06	1.33e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—PTEN—salivary gland cancer	8.94e-06	1.33e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—EP300—salivary gland cancer	8.93e-06	1.33e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—EP300—salivary gland cancer	8.9e-06	1.32e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—CREBBP—salivary gland cancer	8.89e-06	1.32e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—PTEN—salivary gland cancer	8.87e-06	1.32e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—NOTCH1—salivary gland cancer	8.86e-06	1.32e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—salivary gland cancer	8.84e-06	1.32e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—AQP1—salivary gland cancer	8.83e-06	1.31e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CREBBP—salivary gland cancer	8.76e-06	1.3e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—HRAS—salivary gland cancer	8.73e-06	1.3e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—HRAS—salivary gland cancer	8.73e-06	1.3e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—HRAS—salivary gland cancer	8.71e-06	1.3e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—PTEN—salivary gland cancer	8.61e-06	1.28e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CREBBP—salivary gland cancer	8.58e-06	1.28e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—EP300—salivary gland cancer	8.57e-06	1.27e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—HRAS—salivary gland cancer	8.56e-06	1.27e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—EP300—salivary gland cancer	8.52e-06	1.27e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—CCND1—salivary gland cancer	8.51e-06	1.27e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—EP300—salivary gland cancer	8.46e-06	1.26e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CREBBP—salivary gland cancer	8.45e-06	1.26e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism of lipids and lipoproteins—EP300—salivary gland cancer	8.43e-06	1.25e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MAP2K2—salivary gland cancer	8.38e-06	1.25e-05	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—HRAS—salivary gland cancer	8.36e-06	1.24e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—PIK3CA—salivary gland cancer	8.33e-06	1.24e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—HRAS—salivary gland cancer	8.3e-06	1.23e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—PTEN—salivary gland cancer	8.22e-06	1.22e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—EP300—salivary gland cancer	8.22e-06	1.22e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—PTEN—salivary gland cancer	8.19e-06	1.22e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—CREBBP—salivary gland cancer	8.15e-06	1.21e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CREBBP—salivary gland cancer	8.13e-06	1.21e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CREBBP—salivary gland cancer	8.03e-06	1.19e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—PIK3CA—salivary gland cancer	8.01e-06	1.19e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—PIK3CA—salivary gland cancer	8e-06	1.19e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—salivary gland cancer	7.9e-06	1.17e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—EP300—salivary gland cancer	7.84e-06	1.17e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—EP300—salivary gland cancer	7.81e-06	1.16e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—PTEN—salivary gland cancer	7.77e-06	1.16e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—NOTCH1—salivary gland cancer	7.76e-06	1.15e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—HRAS—salivary gland cancer	7.71e-06	1.15e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—CCND1—salivary gland cancer	7.6e-06	1.13e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—PIK3CA—salivary gland cancer	7.58e-06	1.13e-05	CbGpPWpGaD
Dasatinib—JAK2—GPCR downstream signaling—PIK3CA—salivary gland cancer	7.54e-06	1.12e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—PIK3CA—salivary gland cancer	7.49e-06	1.11e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—HRAS—salivary gland cancer	7.41e-06	1.1e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—EP300—salivary gland cancer	7.41e-06	1.1e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—HRAS—salivary gland cancer	7.4e-06	1.1e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—PIK3CA—salivary gland cancer	7.39e-06	1.1e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—PTEN—salivary gland cancer	7.34e-06	1.09e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—TP53—salivary gland cancer	7.25e-06	1.08e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—CCND1—salivary gland cancer	7.2e-06	1.07e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—PTEN—salivary gland cancer	7.17e-06	1.07e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CREBBP—salivary gland cancer	7.03e-06	1.05e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—HRAS—salivary gland cancer	7.01e-06	1.04e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—NUP62—salivary gland cancer	7e-06	1.04e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—EP300—salivary gland cancer	7e-06	1.04e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—PIK3CA—salivary gland cancer	7e-06	1.04e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—PTEN—salivary gland cancer	6.95e-06	1.03e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—VCAN—salivary gland cancer	6.94e-06	1.03e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—HRAS—salivary gland cancer	6.93e-06	1.03e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—PTEN—salivary gland cancer	6.88e-06	1.02e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NOTCH1—salivary gland cancer	6.87e-06	1.02e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—PIK3CA—salivary gland cancer	6.85e-06	1.02e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—PIK3CA—salivary gland cancer	6.85e-06	1.02e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—HRAS—salivary gland cancer	6.84e-06	1.02e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—EP300—salivary gland cancer	6.84e-06	1.02e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—PIK3CA—salivary gland cancer	6.83e-06	1.02e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—PIK3CA—salivary gland cancer	6.69e-06	9.95e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—PIK3CA—salivary gland cancer	6.66e-06	9.9e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—TP53—salivary gland cancer	6.63e-06	9.86e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—EP300—salivary gland cancer	6.63e-06	9.86e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—PIK3CA—salivary gland cancer	6.6e-06	9.83e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—PIK3CA—salivary gland cancer	6.58e-06	9.79e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—EP300—salivary gland cancer	6.56e-06	9.76e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CCND1—salivary gland cancer	6.48e-06	9.65e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—HRAS—salivary gland cancer	6.48e-06	9.63e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PTEN—salivary gland cancer	6.4e-06	9.52e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—TP53—salivary gland cancer	6.39e-06	9.51e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—PTEN—salivary gland cancer	6.35e-06	9.45e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CCND1—salivary gland cancer	6.35e-06	9.45e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—HRAS—salivary gland cancer	6.34e-06	9.43e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—PIK3CA—salivary gland cancer	6.34e-06	9.43e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—HRAS—salivary gland cancer	6.34e-06	9.43e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—HRAS—salivary gland cancer	6.32e-06	9.4e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—PIK3CA—salivary gland cancer	6.31e-06	9.38e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—PTEN—salivary gland cancer	6.26e-06	9.31e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—PIK3CA—salivary gland cancer	6.26e-06	9.31e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CCND1—salivary gland cancer	6.25e-06	9.3e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—salivary gland cancer	6.24e-06	9.28e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CREBBP—salivary gland cancer	6.23e-06	9.26e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—HRAS—salivary gland cancer	6.19e-06	9.2e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—HRAS—salivary gland cancer	6.16e-06	9.16e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—PTEN—salivary gland cancer	6.13e-06	9.12e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—HRAS—salivary gland cancer	6.11e-06	9.09e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—EP300—salivary gland cancer	6.1e-06	9.08e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—HRAS—salivary gland cancer	6.09e-06	9.06e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—PIK3CA—salivary gland cancer	6.08e-06	9.04e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—EP300—salivary gland cancer	6.06e-06	9.01e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—PTEN—salivary gland cancer	6.03e-06	8.98e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CCND1—salivary gland cancer	6.02e-06	8.95e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—EP300—salivary gland cancer	5.97e-06	8.88e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CCND1—salivary gland cancer	5.94e-06	8.84e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—HRAS—salivary gland cancer	5.86e-06	8.72e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—EP300—salivary gland cancer	5.84e-06	8.69e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—CREBBP—salivary gland cancer	5.84e-06	8.69e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—HRAS—salivary gland cancer	5.83e-06	8.68e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PTEN—salivary gland cancer	5.82e-06	8.66e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—PTEN—salivary gland cancer	5.81e-06	8.64e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—PIK3CA—salivary gland cancer	5.8e-06	8.63e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—HRAS—salivary gland cancer	5.79e-06	8.61e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—PIK3CA—salivary gland cancer	5.78e-06	8.6e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—EP300—salivary gland cancer	5.75e-06	8.56e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PTEN—salivary gland cancer	5.73e-06	8.53e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—salivary gland cancer	5.64e-06	8.39e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—HRAS—salivary gland cancer	5.62e-06	8.37e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TP53—salivary gland cancer	5.61e-06	8.34e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—EP300—salivary gland cancer	5.55e-06	8.26e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—EP300—salivary gland cancer	5.54e-06	8.24e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—CREBBP—salivary gland cancer	5.52e-06	8.21e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—PIK3CA—salivary gland cancer	5.48e-06	8.15e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—EP300—salivary gland cancer	5.47e-06	8.14e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—salivary gland cancer	5.38e-06	8e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—HRAS—salivary gland cancer	5.36e-06	7.98e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—HRAS—salivary gland cancer	5.34e-06	7.95e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CCND1—salivary gland cancer	5.2e-06	7.74e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—PIK3CA—salivary gland cancer	5.18e-06	7.7e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—HRAS—salivary gland cancer	5.07e-06	7.54e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—PIK3CA—salivary gland cancer	5.06e-06	7.53e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PTEN—salivary gland cancer	5.02e-06	7.47e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TP53—salivary gland cancer	5.01e-06	7.45e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—PIK3CA—salivary gland cancer	4.9e-06	7.29e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—PIK3CA—salivary gland cancer	4.85e-06	7.22e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—HRAS—salivary gland cancer	4.79e-06	7.13e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—EP300—salivary gland cancer	4.79e-06	7.13e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TP53—salivary gland cancer	4.74e-06	7.05e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—HRAS—salivary gland cancer	4.68e-06	6.96e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CCND1—salivary gland cancer	4.61e-06	6.85e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—HRAS—salivary gland cancer	4.53e-06	6.75e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PIK3CA—salivary gland cancer	4.51e-06	6.71e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—HRAS—salivary gland cancer	4.49e-06	6.68e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—PIK3CA—salivary gland cancer	4.48e-06	6.66e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PTEN—salivary gland cancer	4.45e-06	6.62e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—PIK3CA—salivary gland cancer	4.42e-06	6.57e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CREBBP—salivary gland cancer	4.41e-06	6.55e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—PIK3CA—salivary gland cancer	4.32e-06	6.43e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TP53—salivary gland cancer	4.27e-06	6.36e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—PIK3CA—salivary gland cancer	4.26e-06	6.33e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EP300—salivary gland cancer	4.24e-06	6.31e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TP53—salivary gland cancer	4.18e-06	6.22e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTEN—salivary gland cancer	4.17e-06	6.2e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—HRAS—salivary gland cancer	4.14e-06	6.17e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TP53—salivary gland cancer	4.12e-06	6.13e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PIK3CA—salivary gland cancer	4.11e-06	6.11e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—PIK3CA—salivary gland cancer	4.1e-06	6.1e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—HRAS—salivary gland cancer	4.09e-06	6.08e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PIK3CA—salivary gland cancer	4.05e-06	6.02e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—HRAS—salivary gland cancer	4e-06	5.95e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—salivary gland cancer	3.98e-06	5.92e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—EP300—salivary gland cancer	3.98e-06	5.92e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TP53—salivary gland cancer	3.96e-06	5.9e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTEN—salivary gland cancer	3.94e-06	5.86e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—HRAS—salivary gland cancer	3.94e-06	5.86e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TP53—salivary gland cancer	3.91e-06	5.82e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—HRAS—salivary gland cancer	3.79e-06	5.64e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—EP300—salivary gland cancer	3.76e-06	5.59e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—HRAS—salivary gland cancer	3.74e-06	5.57e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PIK3CA—salivary gland cancer	3.54e-06	5.27e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CREBBP—salivary gland cancer	3.52e-06	5.23e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TP53—salivary gland cancer	3.43e-06	5.1e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—HRAS—salivary gland cancer	3.28e-06	4.88e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTEN—salivary gland cancer	3.15e-06	4.68e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PIK3CA—salivary gland cancer	3.14e-06	4.67e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TP53—salivary gland cancer	3.03e-06	4.51e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—EP300—salivary gland cancer	3e-06	4.46e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CA—salivary gland cancer	2.94e-06	4.38e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—HRAS—salivary gland cancer	2.9e-06	4.32e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CA—salivary gland cancer	2.78e-06	4.13e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CREBBP—salivary gland cancer	2.71e-06	4.04e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTEN—salivary gland cancer	2.51e-06	3.74e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—EP300—salivary gland cancer	2.4e-06	3.56e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CA—salivary gland cancer	2.22e-06	3.3e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTEN—salivary gland cancer	1.94e-06	2.88e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—EP300—salivary gland cancer	1.85e-06	2.75e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CA—salivary gland cancer	1.77e-06	2.64e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CA—salivary gland cancer	1.37e-06	2.03e-06	CbGpPWpGaD
